The healthcare space is an intriguing place to be in these days, with incredible innovations such as GLP-1 drugs (weight-loss drugs like Ozempic and Wegovy) that are rich with growth potential. Additionally, the defensive traits of healthcare stocks make them terrific plays ahead of a potential bout of economic turbulence. Therefore, in this piece, we’ll check in with TipRanks’ Comparison Tool to see which of the following Strong-Buy-rated healthcare stocks analysts prefer for the coming year. E
Eli Lilly rockets 14% after experimental Alzheimer s drug slows rate of decline in trial
Ben WinckJan 12, 2021, 01:17 IST
FILE PHOTO: Lilly logo on a wall of Lilly France, part of Eli Lilly and Co, in Fegersheim, FranceReuters
Eli Lilly rallied as much as 13.8% on Monday after announcing its experimental
Alzheimer s drug significantly slowed the rate of decline in patients.
The drug slowed the decline in patients ability to think by 32% compared to a placebo in the phase 2 trial, according to a press release.
Lilly will present full trial results at a future meeting and submitted data for publication in a peer-reviewed journal.